Adverse events11

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 11 of 11

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Adalimumab	1	7	1
other	Diarrhea	Gastrointestinal disorders	Adalimumab	1	7	1
other	Volume depletion	General disorders	Adalimumab	1	7	1
other	COVID-19	Infections and infestations	Adalimumab	2	7	2
other	Rhinovirus	Infections and infestations	Adalimumab	1	7	1
other	Increased edema	Renal and urinary disorders	Adalimumab	1	7	1
other	eGFR decline (greater than 25% since baseline)	Renal and urinary disorders	Adalimumab	4	7	4
other	Rash	Skin and subcutaneous tissue disorders	Adalimumab	1	7	1
serious	Influenza	Infections and infestations	Adalimumab	1	7	1
serious	Edema	Renal and urinary disorders	Adalimumab	1	7	5
serious	Anasarca and AKI	Renal and urinary disorders	Adalimumab	1	7	4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04009668/events